O'Doherty Catherine, Villoslada Pablo, Vandenbroeck Koen
Applied Genomics Research Group, School of Pharmacy, Queen's University of Belfast, Belfast, UK.
Cytokine Growth Factor Rev. 2007 Jun-Aug;18(3-4):211-22. doi: 10.1016/j.cytogfr.2007.04.012. Epub 2007 May 30.
Interferon-beta (IFN-beta) is routinely prescribed as an immunomodulatory treatment for multiple sclerosis (MS), but is associated with variable clinical efficacy. Ideally an early predictor of response status would allow more rational provision of this therapy. Both pharmacogenomic and expression analysis have highlighted IFN-beta regulated genes which may influence treatment efficacy. In this review we have summarized and discussed the main genes identified by these studies in MS patients, and supplemented this with data from similar studies of Type I IFN treatment in hepatitis.
β-干扰素（IFN-β）通常被用作治疗多发性硬化症（MS）的免疫调节药物，但临床疗效存在差异。理想情况下，早期反应状态预测指标将有助于更合理地应用这种疗法。药物基因组学和表达分析均已发现一些受IFN-β调控的基因，这些基因可能会影响治疗效果。在本综述中，我们总结并讨论了这些研究在MS患者中所确定的主要基因，并补充了来自I型干扰素治疗肝炎类似研究的数据。
